KSKlaus Schmierer

Klaus Schmierer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Klaus Schmierer has a total of 530 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies

    by Ester Valero-Hernandez, Jai Mathur, David Baker, Iris Y. H. Liu, Sarah L. Morgan, Emma C. Tallantyre, Klaus Schmierer, Angray S. Kang

    Background: Natalizumab is a high-efficacy therapy drug for multiple sclerosis that inhibits lymphocyte migration into the central nervous system, increasing lymphocyte counts in the peripheral blood. Anti-drug antibody responses may limit drug efficacy, but current guidance recommends anti-drug antibody testing only after evidence of ‘reduced efficacy’. Objective: To assess the lack of relative lymphocytosis as a biomarker of anti-drug antibody responses. Methods: Lymphocyte counts and immunogenicity data from the pivotal AFFIRM clinical trial ( n = 627 natalizumab vs n = 315 placebo) and real-world data from the Cardiff MS register ( n = 185) were analysed to assess the relationship between lymphocyte counts, anti-drug antibody responses, drug levels and disease activity. Results: Natalizumab treatment induced an absolute change in lymphocyte counts by week 12 (1.40 ± 0.92 vs −0.05 ± 0.62 × 10 9 cells/L in natalizumab vs placebo; p < 0.0001) that was absent in the persistent anti-drug antibody group (−0.12 ± 0.60 × 10 9 cells/L). Increases in lymphocyte counts by ⩾ 0.8 × 10 9 cells/L from the baseline discriminated individuals without anti-drug antibody responses with high sensitivity (≥ 84%) and specificity (≥ 91%). Conclusion: The absence of relative lymphocytosis is associated with anti-drug antibody responses and may provide a simple biomarker to prompt anti-drug antibody testing before disease breakthrough occurs.

  • Open Access

    Diagnosing multiple sclerosis: implementation and unintended effects of the 2024 McDonald criteria

    by Michael A Foster, Charles Wade, Helen L Ford, Klaus Schmierer

    Diagnostic criteria for multiple sclerosis have evolved substantially since the Schumacher criteria were published in 1965. The most recent iteration, the 2024 McDonald diagnostic criteria, was recently released. Each revision has broadened the range of evidence that can support diagnosis while attempting to preserve specificity. The central question raised by the 2024 revision is therefore not simply whether the criteria are valid in principle, but whether they can be applied safely outside expert centres, where imaging quality, laboratory infrastructure and subspecialist interpretation vary substantially. In this review, we evaluate the 2024 criteria not only as a consensus document but as an intervention in clinical behaviour, with particular attention to misdiagnosis risk, operational feasibility and equity of implementation. In particular, we consider the role of the optic nerve and of the central vein sign and paramagnetic rim lesions in diagnosis, and how the criteria bring more diverse populations and presentations into consideration. We also review how the greater options available to achieve a diagnosis may introduce heterogeneity into diagnostic approaches, and what safeguards can be taken to minimize the risk of inappropriate application of the criteria and subsequent misdiagnosis (and inappropriate treatment). The review finishes by proposing how the changes introduced in this iteration might be refined, with more robust definitions on acquiring and interpreting the novel biomarkers.


  • Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study

    by Nicola De Stefano, Patrick Vermersch, Heinz Wiendl, Frederik Barkhof, Xavier Montalban, Anat Achiron, Tobias Derfuss, Andrew Chan, Alexandre Prat, Letizia Leocani, et al.

    Background: The Phase IV MAGNIFY-MS Extension study evaluated the long-term efficacy and durability of cladribine tablets (CladT) in participants with highly active relapsing multiple sclerosis (RMS) during treatment-free Years (Y) 3 and 4. Methods: Data were analysed for all participants and by subgroups (treatment-naïve vs experienced). Time to no evidence of disease activity (NEDA-3) and first confirmed Symbol Digit Modalities Test (SDMT) score change (⩾4/8 point improvement or ⩽4/8 point worsening) were assessed using Kaplan–Meier analysis. SDMT changes were confirmed if sustained across two visits ⩾166 days apart; others were classified as stable. Percentage brain volume change (PBVC) was analysed using the SIENA-XL method. Results: Of 270 MAGNIFY-MS participants, 219 entered MAGNIFY-MS Extension (64.8% female; mean age ± standard deviation: 40.4 ± 9.45 years). NEDA-3 rates were 78.6% (Y3), 79.2% (Y4) and 54.2% (Y3–Y4 combined). At Y4, 83.1% had no T1 gadolinium-enhancing lesions, 67.4% had no active T2 lesions, and the annualised relapse rate was 0.09. Mean annualised PBVC was <0.4% in Y4. SDMT scores were 4/8-point stable or improved in 79.0%/88.1% of participants, and 84.5% had no 6-month confirmed disability progression. Conclusion: Two years of short-course CladT provided sustained clinical and cognitive benefits, supporting the potential for treatment-free remission in RMS. ClinicalTrials.gov Identifier: NCT04783935. Date registered: 3 March, 2021


  • Open Access

    Transfusion‐Associated Graft‐Versus‐Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?

    by Klaus Schmierer, Frederick Chen, David Paling

    Background: Irradiation of cellular blood components prevents transfusion‐associated graft‐versus‐host disease (TA‐GVHD). UK and Spanish guidance recommend lifelong irradiation for all patients treated with purine analogues, including cladribine, irrespective of indication or dose. Objective: To assess whether this approach is justified for people with multiple sclerosis (pwMS) receiving cladribine. Methods: Narrative synthesis of immunological data, hemovigilance evidence, and national European transfusion guidelines. Results: Cladribine used in pwMS induces transient lymphopenia with modest, reversible T‐cell effects and preserved vaccine responsiveness. Since introduction of universal pre‐storage leucocyte depletion, hemovigilance data show no reported cases of TA‐GVHD in this setting. European guidance is heterogeneous, ranging from indefinite to time‐limited or unspecified durations. Conclusion: Current evidence does not clearly support the need for lifelong irradiation after cladribine treatment in pwMS. Time‐limited or individualized approaches merit consideration.

  • Open Access

    Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): A mixed-methods, multi-centre feasibility randomised controlled trial

    by Roshan das Nair, Gogem Topcu, Nia Goulden, Shaun Harris, Jacqueline R Mhizha-Murira, Haley Morris, Polly Swain, Lauren A Taylor, Jonathan Hancock, Laura Price, et al.

    Background: Cognitive difficulties are common in people with multiple sclerosis (pwMS), yet access to neuropsychological rehabilitation is often limited or only provided to those with more severe impairments. The NEuRoMS intervention provides brief, tailored neuropsychological rehabilitation for pwMS with mild-to-moderate cognitive difficulties. Objectives: To evaluate feasibility and acceptability of the intervention and test procedures for a definitive trial. Methods: A mixed-methods, multi-centre feasibility randomised controlled trial (RCT) was conducted. Feasibility outcomes were recruitment, retention, outcome completion, randomisation, intervention delivery and fidelity. Quantitative data were collected at baseline, 3- and 6-months, supplemented by interviews with pwMS and healthcare providers. Results: Seventy-nine participants were randomised (mean age = 54.5 ( SD = 11.5); 70% women) from three UK MS clinics. Most feasibility criteria were met: retention (>80%) and outcome-measure completion (81%–89%) were high, and trial procedures were acceptable. Intervention delivery was feasible and delivered as intended, but staffing-related recruitment challenges need addressing in future trials. Preliminary signal of efficacy was observed, with 3.42-point difference (effect size = 0.48) in the planned primary outcome (MS psychological impact) favouring the intervention, supported by qualitative evidence of sustained behaviour change. Conclusion: The NEuRoMS intervention and trial procedures were feasible and acceptable, with early indication of efficacy. A definitive RCT is underway. Trial registration: ISRCTN11203922; https://doi.org/10.1186/ISRCTN11203922

  • Open Access

    Understanding the Unmet Needs of People with MS at Diagnosis and Throughout Their Care Journey: Insights from a Survey-Based Study

    by Klaus Schmierer, Pieter van Galen, Helen Gray, Alice Laroni, Amanda Montague, Stanca Potra, Heidi Thompson

    Introduction Multiple sclerosis (MS) has a broad range of symptoms and heterogenous trajectory that requires individualised care. To optimise shared decision-making between healthcare professionals (HCPs) and people with MS (PwMS), it is important to understand communication needs from the patient perspective at diagnosis and throughout their care journey. Methods Two multinational online surveys were conducted to explore (1) communication needs around the time of diagnosis, and (2) PwMS empowerment in communicating their specific needs and symptoms. Questionnaires included ten close-ended questions and were shared among 100 PwMS aged 18–50 years in Australia, Spain, the UK and the USA. Anonymised data were analysed by a core panel of HCPs, PwMS and patient advocacy group representatives, and key recommendations were agreed. Results The majority of respondents were female (65–80%) and from the UK (80–87%). PwMS and caregivers are often overwhelmed and feel ‘lost’ at the time of diagnosis. Early regular contact is critical for effective delivery of key information and building a trusting relationship. PwMS value a clear explanation of the healthcare team and next steps, but only around a quarter (26%) had HCP roles clearly explained. PwMS are often uncertain if health changes are related to MS and 42% reported not feeling comfortable discussing ‘invisible’ symptoms such as cognitive, mood and emotional changes. Most respondents (54%) reported that their MS nurse was the person they were most likely to consult. Support services were not routinely offered; only 26% were informed about patient support groups. The most reported benefit of an MS-specific patient group was ‘feeling less alone’. Conclusion Regular HCP contact after diagnosis, peer group support for PwMS and their caregivers, signposting of reliable and accurate online resources and the timely offer of support services, including psychological support, should be routine elements of care from the point of diagnosis.

  • Open Access

    Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

    by Heinz Wiendl, Frederik Barkhof, Xavier Montalban, Anat Achiron, Tobias Derfuss, Andrew Chan, Suzanne Hodgkinson, Alexandre Prat, Letizia Leocani, Klaus Schmierer, et al.

    This animated video presents the MAGNIFY-MS study, which investigated immune changes following cladribine tablets treatment of relapsing MS.


  • Open Access

    Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study

    by Klaus Schmierer, Heinz Wiendl, Frederik Barkhof, Xavier Montalban, Anat Achiron, Tobias Derfuss, Andrew Chan, Suzanne Hodgkinson, Alexandre Prat, Letizia Leocani, et al.

    Background: Cladribine, an oral prodrug, penetrates the blood–brain barrier, impacting biomarkers of disease progression within the central nervous system. Objectives: Describe disease activity in cladribine tablets (CladT)-treated people with highly active relapsing multiple sclerosis (pwRMS) using clinical outcomes and biomarkers. Design: MAGNIFY-MS was an open-label, single-arm, phase IV trial with four sub-studies. Participants were grouped by previous treatment (Tx); Tx-naïve versus Tx-experienced; those with previous exposure to second-line therapies were excluded. This analysis describes cerebrospinal fluid (CSF) and optical coherence tomography (OCT) sub-studies. CSF sub-study participants were stratified by the number of oligoclonal bands (OCBs) at baseline (≥2/≥4). Methods: Logistic regression analysis is reported for no evidence of disease activity (NEDA)-3 and no evidence of progression or active disease (NEPAD) at Year (Y)1 and Y2, and annualized relapse rate (ARR) at Y2. Changes in intrathecal (OCBs, kappa free light chain [KFLC], immunoglobulin [Ig]G and IgM indices), OCT measures, and neuroaxonal degeneration (neurofilament light chain [NfL]) biomarkers are reported at baseline, month (M)12, and M24. Results: MAGNIFY-MS included 270 pwRMS; 28 and 36 were included in the CSF and OCT sub-studies, respectively. In Y2, estimated rates of NEDA-3 were 64.1% overall and 69.1% in the Tx-naïve group. The estimated rate of NEPAD overall was 60.2% in Y2. The estimated ARR was 0.09 from baseline to M24 (Tx-naïve participants, 0.04). In participants with ≥2 OCBs at baseline ( n = 17), 76.5% had OCB reduction or disappearance at least once in the study. KFLC and IgG indices were reduced at M24 versus baseline. Sustained reductions were observed in median NfL, while IgG and IgM remained within normal ranges for most participants. Mean OCT measurements showed no retinal nerve fiber thinning. Conclusion: For CladT-treated pwRMS, disease activity and biomarkers of intrathecal inflammation and neuroaxonal damage were reduced versus baseline. Trial registration: ClinicalTrials.gov identifier, NCT03364036. Date registered: June 12, 2017. Date first patient enrolled: May 28, 2018. https://clinicaltrials.gov/study/NCT03364036 . Extension study ClinicalTrials.gov Identifier: NCT04783935. Date registered: March 05, 2021. Date first patient enrolled: March 10, 2021. https://clinicaltrials.gov/study/NCT04783935 .


  • Mechanistic biology linking traumatic brain injury to multiple sclerosis susceptibility

    by David Baker, Lars Alfredsson, Anna Karin Hedström, Klaus Schmierer

    Multiple sclerosis (MS) is a major, immune-mediated, demyelinating disease and the major cause of non-traumatic disability in young adults. Susceptibility to disease is controlled by a variety of interacting features that include genetic and notably environmental factors. One of these risk factors appears to be the occurrence of traumatic brain injury. In a follow-on to previous analysis of head injury-induced risk factors for MS, analysis of Swedish Registry data of MS and matched controls demonstrates enhanced susceptibility to MS, notably when stratified for the presence of HLA-DRB1*15.01, absence of HLA-A*02.01 and occurrence of smoking, which are known risk factors, the risk of MS increases to OR 65.4 (95% CI 8.35 to 512). This can be mechanistically supported by a number of routes whereby brain injury can lead to expression of autoantigenic targets, or damage-related release of neuroantigens that could generate a novel autoantigenic response in draining lymph nodes following glymphatic/meningeal lymphatic drainage. These may be different from other mechanisms that are relevant to susceptibility due to human leucocyte antigen expression and smoking.